论文部分内容阅读
膀胱内灌注药物的种类日益增多,这对延迟或防止浅表性移行细胞癌侵犯肌层来讲是有效的,从而推迟了全膀胱切除的时间。但在重复和延长灌注的过程中,前列腺尿路上皮仍暴露于致癌因素的作用之下,因而在前列腺内仍有形成和发生移行细胞癌的危险性。Droller与Walsh1985年报道了膀胱癌灌注治疗过程中发生前列腺移行细胞癌的3例病人。Catalona等(1987)亦曾报道在膀胱灌注时8例病人的移行细胞癌累及前列腺。本文作者在1983—1986年对63例男性浅表性膀胱癌行丝裂霉素、BCG和/或Thio—tepa膀胱内灌注治疗,其中10例在一种或数种药物灌注后3—
Intravesical instillation of drugs is increasing, which is effective in delaying or preventing the superficial transitional cell carcinoma from invading the muscular layer, thereby delaying the time for full cystectomy. However, in the process of repeated and prolonged perfusion, the prostatic urothelium is still exposed to the effects of carcinogenic factors, and thus there is still the risk of formation and transitional cell cancer in the prostate. Droller and Walsh reported in 1985 three cases of transitional cell carcinoma of the prostate during bladder cancer perfusion. Catalona et al. (1987) also reported transitional cell carcinoma of the 8 patients with prostate involvement during bladder perfusion. The authors performed intravesical instillation of mitomycin, BCG and/or Thio-tepa in 63 cases of superficial bladder cancer in males from 1983 to 1986, of which 10 cases were treated with one or several drugs 3